NASDAQ: SLXNSilexion Therapeutics Corp Stock
$1.80-0.10 (-5.26%)
Updated Aug 5, 2026
SLXN Price
$1.80
Fair Value Price
N/A
Market Cap
$754.19k
52 Week Low
$1.50
52 Week High
$86.00
P/E
-0.03x
P/B
2.59x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$16.38M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
14.81
Operating Cash Flow
-$12M
Beta
0.81
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SLXN Overview
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SLXN's potential to beat the market
- SLXN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SLXN
RankedUnranked of 465
RankedUnranked of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.75 | A | |
| $110.69 | A | |
| $8.11 | A |
Be the first to know about important SLXN news, forecast changes, insider trades & much more!
SLXN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SLXN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SLXN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SLXN is good value based on its book value relative to its share price (2.59x), compared to the US Biotechnology industry average (5.31x)
P/B vs Industry Valuation
SLXN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SLXN due diligence checks available for Premium users.
Valuation
SLXN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.03x
Industry
14.89x
Market
14.23x
SLXN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.59x
Industry
5.31x
SLXN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SLXN's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.7M
Profit Margin
0%
SLXN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.6M
Liabilities
$4.3M
Debt to equity
14.81
SLXN's short-term assets ($4.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLXN's short-term assets ($4.07M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLXN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SLXN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.6M
Investing
$0.0
Financing
$83.0k
SLXN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SLXN vs Biotech Stocks
Silexion Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.